NASDAQ: CALC
Calcimedica Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their CALC stock forecasts and price targets.

Forecast return on equity

Is CALC forecast to generate an efficient return?

Forecast return on assets

Is CALC forecast to generate an efficient return on assets?

Company
-294.68%
Industry
22.59%
CALC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CALC earnings per share forecast

What is CALC's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.72
Avg 2 year Forecast
-$1.94
Avg 3 year Forecast
-$3.05

CALC revenue forecast

What is CALC's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$20.4M

CALC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CALC$4.37N/AN/A
CYPH$1.11N/AN/A
PMVP$1.19N/AN/A
ATHE$3.42N/AN/A
DOMH$3.89N/AN/A

Calcimedica Stock Forecast FAQ

What is CALC's earnings growth forecast for 2025-2027?

(NASDAQ: CALC) Calcimedica's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 73.4%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 104.81%.

Calcimedica's earnings in 2025 is -$23,060,000.On average, 6 Wall Street analysts forecast CALC's earnings for 2025 to be -$24,838,977, with the lowest CALC earnings forecast at -$24,288,537, and the highest CALC earnings forecast at -$25,115,638. On average, 6 Wall Street analysts forecast CALC's earnings for 2026 to be -$27,998,965, with the lowest CALC earnings forecast at -$30,219,459, and the highest CALC earnings forecast at -$25,266,937.

In 2027, CALC is forecast to generate -$43,945,883 in earnings, with the lowest earnings forecast at -$42,222,515 and the highest earnings forecast at -$45,238,409.

If you're new to stock investing, here's how to buy Calcimedica stock.

What is CALC's revenue growth forecast for 2025-2027?

(NASDAQ: CALC) Calcimedica's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 286.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.59%.

Calcimedica's revenue in 2025 is $0.On average, 6 Wall Street analysts forecast CALC's revenue for 2025 to be $0, with the lowest CALC revenue forecast at $0, and the highest CALC revenue forecast at $0. On average, 6 Wall Street analysts forecast CALC's revenue for 2026 to be $0, with the lowest CALC revenue forecast at $0, and the highest CALC revenue forecast at $0.

In 2027, CALC is forecast to generate $293,952,392 in revenue, with the lowest revenue forecast at $282,424,848 and the highest revenue forecast at $302,598,051.

What is CALC's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: CALC) forecast ROA is -294.68%, which is lower than the forecast US Biotechnology industry average of 22.59%.

What is CALC's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CALC) Calcimedica's current Earnings Per Share (EPS) is -$1.62. On average, analysts forecast that CALC's EPS will be -$1.72 for 2025, with the lowest EPS forecast at -$1.69, and the highest EPS forecast at -$1.74. On average, analysts forecast that CALC's EPS will be -$1.94 for 2026, with the lowest EPS forecast at -$2.10, and the highest EPS forecast at -$1.75. In 2027, CALC's EPS is forecast to hit -$3.05 (min: -$2.93, max: -$3.14).

What is CALC's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: CALC) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.